Cytek Biosciences マネジメント
マネジメント 基準チェック /34
Cytek Biosciencesの CEO はWenbin Jiangで、 Dec2014年に任命され、 の在任期間は 11.42年です。 の年間総報酬は$ 5.12Mで、 12.1%給与と87.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の4.24%を直接所有しており、その価値は$ 21.69M 。経営陣と取締役会の平均在任期間はそれぞれ4年と4.4年です。
主要情報
Wenbin Jiang
最高経営責任者
US$5.1m
報酬総額
| CEO給与比率 | 12.11% |
| CEO在任期間 | 11.4yrs |
| CEOの所有権 | 4.2% |
| 経営陣の平均在職期間 | 4yrs |
| 取締役会の平均在任期間 | 4.4yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 04
CTKB: 2026 Outlook And Completed Buyback Will Support Balanced Multi Year Setup
Analysts have revised their price target on Cytek Biosciences slightly, making a modest change that reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E, while keeping the fair value estimate steady at $5.00. What's in the News Cytek Biosciences reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares for $0 million, and completed a total buyback of 3,292,588 shares, or 2.56%, for $15.3 million under the program announced on December 30, 2024 (Key Developments).
ナラティブの更新 • Apr 20
CTKB: Share Repurchases And 2026 Guidance Will Support Future Upside Potential
Analysts have kept their $6.00 price target for Cytek Biosciences unchanged, with only small tweaks to inputs such as discount rate, profit margin assumptions, and future P/E. These adjustments support the view that the current valuation remains aligned with their updated models.ナラティブの更新 • Apr 06
CTKB: 2026 Guidance And Buyback Will Frame Balanced Multi Year Upside Potential
Narrative Update Analysts have lifted their price target on Cytek Biosciences to $5 from $4, pointing to a clearer multi year framework and several potential growth drivers as key reasons for the change. Analyst Commentary Analysts highlighting the higher US$5 price target frame Cytek Biosciences as a name that could benefit if the broader diagnostic tools group sees improving sentiment and clearer multi year guidance.ナラティブの更新 • Mar 22
CTKB: Sector Recovery And 2026 Guidance Will Support Upside Potential
Analysts have raised the target price on Cytek Biosciences shares to $5 from $4, citing improving sentiment in diagnostic tools and a preference for companies with clearer multi year growth frameworks and several potential upside drivers. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$5 target as a reflection of improving sentiment across diagnostic tools, which supports a more constructive stance on valuation for Cytek Biosciences.ナラティブの更新 • Mar 08
CTKB: Sector Recovery And 2026 Guidance Are Expected To Drive Upside
Analysts have modestly raised their price target framework on Cytek Biosciences to $6.00, supported by a shift toward higher future P/E assumptions and recent Street research that highlights clearer multi year growth pathways and improving investor sentiment in the diagnostic tools group. Analyst Commentary Recent research points to a more constructive stance on Cytek Biosciences, with price targets nudged higher and a focus on how the company fits into a potential recovery in the diagnostic tools group.ナラティブの更新 • Feb 22
CTKB: 2026 Guidance And Multi Year Framework Will Support Upside Potential
Analysts recently lifted Cytek Biosciences' price target to $5 from $4, pointing to a more supportive sector backdrop, higher revenue growth assumptions, and a slightly higher future P/E multiple. They noted that they are focused on companies with clear multi year frameworks and multiple potential growth drivers.分析記事 • Feb 13
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump
The Cytek Biosciences, Inc. ( NASDAQ:CTKB ) share price has fared very poorly over the last month, falling by a...ナラティブの更新 • Feb 08
CTKB: 2026 Guidance Will Underpin Multi Year Upside Framework
Analysts have lifted their price target on Cytek Biosciences to $5 from $4, pointing to improving sentiment around the diagnostic tools group and an interest in companies that offer clear multi year growth frameworks with several potential upside drivers. Analyst Commentary Analysts framing Cytek Biosciences around a US$5 price target are generally pointing to companies in the diagnostic tools group that offer clear multi year plans and several possible levers for upside.
ナラティブの更新 • Jan 24
CTKB: Sector Recovery And 2026 Earnings Framework Will Drive Repricing
Analysts have raised their price target on Cytek Biosciences to $5.00 from $4.00, citing refined assumptions around fair value, discount rates, growth, margins, and future P/E as they reassess the company within a recovering diagnostics tools sector. Analyst Commentary Bullish analysts are framing the move to a US$5.00 price target as part of a broader reset across diagnostic tools names, with Cytek Biosciences seen as one of the names that screens well under updated fair value and discount rate assumptions.ナラティブの更新 • Jan 10
CTKB: 2026 Guidance And European Expansion Will Shape Multi Year Framework
Narrative Update Analysts have lifted their price target on Cytek Biosciences to US$5.00 from US$4.00, citing a clearer multi year growth framework, multiple potential growth drivers, and a view that updated 2026 guidance will be important for how the stock fits into a broader sector recovery. Analyst Commentary Recent research highlights a more defined multi year framework for Cytek Biosciences, with attention on how upcoming 2026 guidance could shape market views on growth and sector positioning.ナラティブの更新 • Dec 17
CTKB: European Expansion Will Drive Future Upside Potential
Analysts have maintained their price target for Cytek Biosciences at $5.75, with only minor model refinements to the discount rate, revenue growth expectations, and profit margin assumptions supporting a steady valuation outlook. What's in the News Reaffirmed full year 2025 revenue guidance of $196 million to $205 million, implying growth of -2% to +2% versus 2024, assuming stable currency exchange rates (company guidance) Completed previously announced share repurchase program, buying back 3,292,588 shares, or 2.56% of shares outstanding, for a total of $15.3 million, with no additional shares repurchased in the July 1 to September 30, 2025 period (company disclosure) Relocated and expanded European headquarters to a larger facility in the Life Sciences District of Amsterdam, adding over 40% more space, a warehouse, and a dedicated customer service and training center to support growth in the EMEA region (company announcement) Brought European warehouse operations in house as part of a strategic push to scale the reagent business, aiming to improve quality control, operational efficiency, and turnaround times for customers (company announcement) Valuation Changes Consensus Analyst Price Target (Fair Value): unchanged at $5.75 per share, indicating no shift in overall valuation outlook.ナラティブの更新 • Dec 03
CTKB: Full Year Outlook And Europe Expansion Will Shape Balanced Future Prospects
Analysts have raised their price target on Cytek Biosciences by approximately 12 percent to about 6 dollars per share, citing slightly stronger expectations for long term revenue growth, improved profit margin potential, and a modestly higher future earnings multiple. What's in the News Reaffirmed full year 2025 revenue guidance of 196 million to 205 million dollars, implying flat to modest growth of minus 2 percent to plus 2 percent versus 2024 (company guidance).分析記事 • Nov 22
Revenues Tell The Story For Cytek Biosciences, Inc. (NASDAQ:CTKB) As Its Stock Soars 43%
The Cytek Biosciences, Inc. ( NASDAQ:CTKB ) share price has done very well over the last month, posting an excellent...Seeking Alpha • Nov 20
Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth
Summary Cytek Biosciences offers a full-spectrum cytometry platform. This means they provide instruments, reagents, services, and cloud software. Their main value proposition is to allow clients to achieve higher-parameter cell analysis than conventional flow systems. Its core product portfolio centers around Aurora, Northern Lights, Aurora CS, and Aurora Evo. Each targets a different price-performance tier. Over time, CTKB should continue growing its reagents and service businesses while creating higher-margin recurring revenue. Ultimately, I think the company's valuation multiples and ample cash runway support a bullish rating. Thus, I rate it a 'Buy' at these levels. Read the full article on Seeking Alpha分析記事 • Aug 15
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
NasdaqGS:CTKB 1 Year Share Price vs Fair Value Explore Cytek Biosciences's Fair Values from the Community and select...ナラティブの更新 • Aug 10
Cloud Software And Flow Cytometry Will Unlock Global Opportunity
The consensus price target for Cytek Biosciences has been notably reduced, primarily due to a significant downward revision in revenue growth forecasts, resulting in a new fair value of $5.00 per share. What's in the News Full-year 2025 revenue guidance narrowed to $196 million–$205 million, representing growth of -2% to +2% over the prior year.分析記事 • Jul 28
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...新しいナラティブ • May 31
APAC Markets And Recurring Revenues Will Support Life Sciences
Growth in Asia-Pacific and strong recurring revenues from services and reagents offset weaker performance in the US and Europe, supporting long-term stability.分析記事 • May 30
The Market Doesn't Like What It Sees From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Yet As Shares Tumble 31%
To the annoyance of some shareholders, Cytek Biosciences, Inc. ( NASDAQ:CTKB ) shares are down a considerable 31% in...Seeking Alpha • Apr 28
Why Cytek Biosciences Should Beat Q1 Earnings Expectations
Summary There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitability potential, supported by effective cost management and a solid balance sheet. Despite a 41% YTD stock decline, Cytek's innovative FSP tech and growing Cytek Cloud user base signal strong future growth prospects. Valuation analysis suggests a 22% upside in CTKB stock, with a price target of $4.6/share, assuming continued margin expansion and positive earnings trajectory. Read the full article on Seeking Alpha分析記事 • Apr 16
Is Cytek Biosciences (NASDAQ:CTKB) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Feb 13
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Cytek Biosciences, Inc. ( NASDAQ:CTKB ) shares have had a horrible month, losing 28% after a relatively good period...Seeking Alpha • Jan 09
Upgrading Cytek Biosciences Stock On An Upcoming Catalyst
Summary I'm upgrading Cytek Biosciences from "Hold" to "Buy" due to improving financials, expanding installed base, and strong demand for Aurora and Northern Lights systems. Cytek's Q3 FY2024 revenue up 7% YoY, driven by international demand; service revenue surged 25% YoY, boosting recurring revenue streams. The recently announced buyback plan went unnoticed, based on the EPS estimates revisions. I'm also expecting a potential catalyst from the upcoming J.P. Morgan Healthcare Conference, which could further drive CTKB stock price recovery and growth in 2025. Despite risks, CTKB's global expansion, technological advancements, and sound financials position it well for long-term shareholder value creation. Read the full article on Seeking Alpha分析記事 • Dec 16
Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Nov 07
Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump
Cytek Biosciences, Inc. ( NASDAQ:CTKB ) shareholders would be excited to see that the share price has had a great...分析記事 • Sep 13
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
With a median price-to-sales (or "P/S") ratio of close to 3.6x in the Life Sciences industry in the United States, you...分析記事 • Aug 09
An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Key Insights Cytek Biosciences' estimated fair value is US$10.66 based on 2 Stage Free Cash Flow to Equity Current...分析記事 • Jul 12
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Jun 04
Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
It's not a stretch to say that Cytek Biosciences, Inc.'s ( NASDAQ:CTKB ) price-to-sales (or "P/S") ratio of 3.6x right...Seeking Alpha • Mar 20
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Summary Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth above 15% since IPO. Cytek's technological advantage, broadening ecosystem, and potential in the clinical and biopharma space contribute to the leading financials and positive outlook. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$74m |
| Dec 31 2025 | US$5m | US$620k | -US$67m |
| Sep 30 2025 | n/a | n/a | -US$13m |
| Jun 30 2025 | n/a | n/a | -US$6m |
| Mar 31 2025 | n/a | n/a | -US$11m |
| Dec 31 2024 | US$6m | US$599k | -US$6m |
| Sep 30 2024 | n/a | n/a | -US$10m |
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$12m |
| Dec 31 2023 | US$5m | US$578k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$4m | US$524k | US$3m |
| Sep 30 2022 | n/a | n/a | -US$901k |
| Jun 30 2022 | n/a | n/a | -US$3m |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | US$5m | US$375k | US$52k |
| Sep 30 2021 | n/a | n/a | US$575k |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | US$4m |
| Dec 31 2020 | US$422k | US$241k | US$3m |
報酬と市場: Wenbinの 総報酬 ($USD 5.12M ) は、 US市場 ($USD 2.65M ) の同規模の企業の平均を上回っています。
報酬と収益: Wenbinの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Wenbin Jiang (61 yo)
11.4yrs
在職期間
US$5,120,061
報酬
Dr. Wenbin Jiang, Ph D., is co-founder, Chairman and President of Cytek Biosciences, Inc and has been its Chief Executive Officer and Director since December 2014. Dr. Jiang is a seasoned entrepreneur and...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 11.4yrs | US$5.12m | 4.24% $ 21.7m | |
| Chief Financial Officer | 2.2yrs | US$2.46m | 0.086% $ 440.3k | |
| CTO & Director | 11.3yrs | US$1.46m | 3.82% $ 19.5m | |
| Chief Legal Officer & Corporate Secretary | 5.3yrs | US$2.17m | 0.12% $ 594.0k | |
| Senior Vice President of Global Sales & Services | 2.8yrs | US$1.02m | 0.034% $ 172.1k | |
| Head of Investor Relations | no data | データなし | データなし | |
| Head of Corporate Development Analytics | 2.2yrs | US$758.17k | 0% $ 0 |
4.0yrs
平均在職期間
60yo
平均年齢
経験豊富な経営陣: CTKBの経営陣は 経験豊富 であると考えられます ( 4年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 11.4yrs | US$5.12m | 4.24% $ 21.7m | |
| CTO & Director | 11.3yrs | US$1.46m | 3.82% $ 19.5m | |
| Lead Independent Director | 3.9yrs | US$272.08k | 0.012% $ 62.2k | |
| Independent Director | 7.7yrs | US$257.92k | 0.033% $ 169.1k | |
| Independent Director | 1.9yrs | US$254.02k | 0.013% $ 66.2k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 4.4yrs | US$247.50k | 0.012% $ 62.2k | |
| Member of Scientific Advisory Board | 2.3yrs | データなし | データなし |
4.4yrs
平均在職期間
62.5yo
平均年齢
経験豊富なボード: CTKBの 取締役会 は 経験豊富 であると考えられます ( 4.4年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 13:38 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cytek Biosciences, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |
| Kallum Titchmarsh | Morgan Stanley |